RxDoctor Payments Data

Matthew Edwards, DO

Interventional Cardiology · Pontiac, MINPI 1073877098

Payments from drug & device makers

$14,398in general payments, 2019–2025

Across 381 payments — averaging $37.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$3K
  • Abbott$2K
  • Boston Scientific$2K
  • Novartis$904
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$694
  • Kestra Medical Technology Services, Inc.$648
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$3,37823%
  • Food & beverage$10,90876%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,398 in reported general payments places this provider in the 55th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$277,689
Medicare patients
944
Services billed
3,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$369,655
XareltoRivaroxaban154$199,467
EntrestoSacubitril/Valsartan94$146,984
Repatha SureclickEvolocumab121$92,411
FarxigaDapagliflozin Propanediol18$22,885
Praluent PenAlirocumab22$15,113
Pitavastatin Calcium17$8,489
Amiodarone Hcl111$8,002
Atorvastatin Calcium507$7,790
Metoprolol Succinate360$7,244
Rosuvastatin Calcium276$5,082
Ezetimibe200$4,861
Ranolazine ErRanolazine16$2,640
ClopidogrelClopidogrel Bisulfate144$2,442
Losartan Potassium134$2,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$253$369,655293 claims
Johnson & JohnsonXarelto$459$199,467154 claims
NovartisEntresto$904$146,98494 claims
AstraZenecaFarxiga$327$22,88518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →